An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome

开始日期2019-10-12

申办/合作机构

ChemoCentryx, Inc.

NCT03703908 / Terminated临床2期

An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome

An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome

开始日期2018-10-01

申办/合作机构

ChemoCentryx, Inc.

EUCTR2017-003021-15-FR / Not yet recruiting临床2期

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with Focal Segmental Glomerulosclerosis (FSGS)

开始日期2018-05-18

申办/合作机构

ChemoCentryx, Inc.

100 项与 CCX-140 相关的临床结果

登录后查看更多信息

100 项与 CCX-140 相关的转化医学

登录后查看更多信息

100 项与 CCX-140 相关的专利（医药）

登录后查看更多信息

项与 CCX-140 相关的文献（医药）

2022-02-28·Cochrane Database of Systematic Reviews

Interventions for focal segmental glomerulosclerosis in adults.

Review

作者: Sinha, Aditi ; Hodson, Elisabeth M ; Cooper, Tess E

BACKGROUND:

Focal segmental glomerulosclerosis (FSGS) can be separated into primary, genetic or secondary causes. Primary disease results in nephrotic syndrome while genetic and secondary forms may be associated with asymptomatic proteinuria or with nephrotic syndrome. Overall only about 20% of patients with FSGS experience a partial or complete remission of nephrotic syndrome with treatment. FSGS progresses to kidney failure in about half of the cases. This is an update of a review first published in 2008.

OBJECTIVES:

To assess the benefits and harms of immunosuppressive and non-immunosuppressive treatment regimens in adults with FSGS.

SEARCH METHODS:

We searched the Cochrane Kidney and Transplant Register of Studies to 21 June 2021 through contact with the Information Specialist using search terms relevant to this review. Studies in the Register are identified through searches of CENTRAL, MEDLINE, and EMBASE, conference proceedings, the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.

SELECTION CRITERIA:

Randomised controlled trials (RCTs) and quasi-RCTs of any intervention for FSGS in adults were included. Studies comparing different types, routes, frequencies, and duration of immunosuppressive agents and non-immunosuppressive agents were assessed.

DATA COLLECTION AND ANALYSIS:

At least two authors independently assessed study quality and extracted data. Statistical analyses were performed using the random-effects model and results were expressed as a risk ratio (RR) for dichotomous outcomes, or mean difference (MD) for continuous data with 95% confidence intervals (CI). Confidence in the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

MAIN RESULTS:

Fifteen studies (560 participants) were included. No studies specifically evaluating corticosteroids compared with placebo or supportive therapy were identified. Studies evaluated participants with steroid-resistant FSGS. Five studies (240 participants) compared cyclosporin with or without prednisone with different comparators (no specific treatment, prednisone, methylprednisolone, mycophenolate mofetil (MMF), dexamethasone). Three small studies compared monoclonal antibodies (adalimumab, fresolimumab) with other agents or placebo. Six single small studies compared rituximab with tacrolimus, cyclosporin plus valsartan with cyclosporin alone, MMF with prednisone, chlorambucil plus methylprednisolone and prednisone with no specific treatment, different regimens of dexamethasone and CCX140-B (an antagonist of the chemokine receptor CCR2) with placebo. The final study (109 participants) compared sparsentan, a dual inhibitor of endothelin Type A receptor and of the angiotensin II Type 1 receptor, with irbesartan. In the risk of bias assessment, seven and five studies were at low risk of bias for sequence generation and allocation concealment, respectively. Four studies were at low risk of performance bias and 14 studies were at low risk of detection bias. Thirteen, six and five studies were at low risk of attrition bias, reporting bias and other bias, respectively. Of five studies evaluating cyclosporin, four could be included in our meta-analyses (231 participants). Cyclosporin with or without prednisone compared with different comparators may increase the likelihood of complete remission (RR 2.31, 95% CI 1.13 to 4.73; I² = 1%; low certainty evidence) and of complete or partial remission (RR 1.64, 95% CI 1.10 to 2.44; I² = 19%) but not of partial remission (RR 1.36, 95% CI 0.78 to 2.39, I² = 22%). In Individual studies, cyclosporin with prednisone versus prednisone may increase the likelihood of partial (49 participants: RR 7.96, 95% CI 1.09 to 58.15) or complete or partial remission (49 participants: RR 8.85, 95% CI 1.22 to 63.92) but not of complete remission. The remaining individual comparisons may make little or no difference to the likelihood of complete remission, partial remission or complete or partial remission compared with no treatment, methylprednisolone, MMF, or dexamethasone. Individual study data and combined data showed that cyclosporin may make little or no difference to the outcomes of chronic kidney disease or kidney failure. It is uncertain whether cyclosporin compared with these comparators in individual or combined analyses makes any difference to the outcomes of hypertension or infection. MMF compared with prednisone may make little or no difference to the likelihood of complete remission (33 participants: RR 1.05, 95% CI 0.58 to 1.88; low certainty evidence), partial remission, complete or partial remission, glomerular filtration rate, or infection. It is uncertain whether other interventions make any difference to outcomes as the certainty of the evidence is very low. It is uncertain whether sparsentan reduces proteinuria to a greater extent than irbesartan.

AUTHORS' CONCLUSIONS:

No RCTs, which evaluated corticosteroids, were identified although the KDIGO guidelines recommend corticosteroids as the first treatment for adults with FSGS. The studies identified included participants with steroid-resistant FSGS. Treatment with cyclosporin for at least six months was more likely to achieve complete remission of proteinuria compared with other treatments but there was considerable imprecision due to few studies and small participant numbers. In future studies of existing or new interventions, the investigators must clearly define the populations included in the study to provide appropriate recommendations for patients with primary, genetic or secondary FSGS.

2022-01-01·The Journal of clinical endocrinology and metabolism2区 · 医学

Novel Therapies for Kidney Disease in People With Diabetes

2区 · 医学

Review

作者: Ekinci, Elif I ; MacIsaac, Richard J ; Coughlan, Melinda T ; Khurana, Nayana ; James, Steven

Abstract:

Context:

The increasing burden of diabetic kidney disease (DKD) has led to the discovery of novel therapies.

Objective:

This review aims to summarize the results of recent clinical trials that test the efficacy of potential therapies for DKD.

Methods:

A systematized narrative review was performed utilizing the PubMed, Embase (Ovid), CINAHL, and Cochrane databases (January 2010 to January 2021). The included trials assessed the efficacy of specific medications using renal endpoints in adult participants with type 1 or 2 diabetes.

Results:

Fifty-three trials were identified. Large, multinational, and high-powered trials investigating sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrated improved renal outcomes, even in patients with established DKD. Trials examining incretin-related therapies also showed some improvement in renal outcomes. Additionally, mineralocorticoid receptor antagonists exhibited potential with multiple improved renal outcomes in large trials, including those involving participants with established DKD. Atrasentan, baricitinib, ASP8232, PF-04634817, CCX140-B, atorvastatin, fenofibrate, probucol, doxycycline, vitamin D, omega-3 fatty acids, silymarin, turmeric, total glucosides of paeony, and tripterygium wilfordii Hook F extract were all associated with some improved renal endpoints but need further exploration. While bardoxolone methyl was associated with a decrease in albuminuria, high rates of cardiovascular adverse effects curtailed further exploration into this agent. Selonsertib, allopurinol, praliciguat, palosuran, benfotiamine, and diacerein were not associated with improved renal outcomes.

Conclusion:

Trials have yielded promising results in the search for new therapies to manage DKD. SGLT2 inhibitors and incretin-related therapies have demonstrated benefit and were associated with improved cardiovascular outcomes. Mineralocorticoid receptor antagonists are another class of agents with increasing evidence of benefits.

2015-09-01·The lancet. Diabetes & endocrinology1区 · 医学

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial

1区 · 医学

Article

作者: Bekker, Pirow ; Hasslacher, Christopher ; Gouni-Berthold, Ioanna ; Henkel, Elena ; Potarca, Antonia ; Mehling, Heidrun ; Schall, Thomas J ; de Zeeuw, Dick ; Heerspink, Hiddo J Lambers ; Tesar, Vladimir

BACKGROUND:

Patients with type 2 diabetes and nephropathy have high cardiorenal morbidity and mortality despite optimum treatment including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Residual risk is related to residual albuminuria. We assessed whether CCX140-B, a selective inhibitor of C-C chemokine receptor type 2 (CCR2), could further reduce albuminuria when given in addition to standard care, including ACE inhibitors or ARBs.

METHODS:

In this randomised, double-blind, placebo-controlled clinical trial, we recruited patients from 78 research centres in Belgium, Czech Republic, Germany, Hungary, Poland, and the UK. We enrolled patients with type 2 diabetes aged 18-75 years with proteinuria (first morning void urinary albumin to creatinine ratio [UACR] 100-3000 mg/g), estimated glomerular filtration rate of 25 mL/min per 1·73 m(2) or higher, and taking stable antidiabetic treatment and ACE inhibitors or ARBs, for at least 8 weeks before study entry. Patients were stratified based on baseline UACR and renal function (estimated glomerular filtration rate), and then randomly assigned (1:1:1) via an interactive web response system with a minimisation algorithm to oral placebo, 5 mg CCX140-B, or 10 mg CCX140-B once a day. The 12-week dosing period in the initial protocol was extended to 52 weeks by protocol amendment. The primary efficacy measure was change from baseline in UACR during 52 weeks in the modified intention-to-treat population (all patients with uninterrupted dosing, excluding patients who stopped dosing at week 12 either permanently under the original protocol, or temporarily because of delay in approval of the protocol amendment). We did safety analyses on all randomly assigned patients who received at least one dose of study drug. According to a prespecified analysis plan, we analysed the primary endpoint with one-sided statistical testing with calculation of upper 95% confidence limits of the differences between active and control. This trial is registered with ClinicalTrials.gov, number NCT01447147.

FINDINGS:

The study ran from Dec 7, 2011 (first patient enrolled), until Aug 4, 2014. We enrolled 332 patients: 111 were assigned to receive placebo, 110 to 5 mg CCX140-B, and 111 to 10 mg CCX140-B. Of these, 192 were included in the modified intention-to-treat population. UACR changes from baseline during 52 weeks were -2% for placebo (95% CI -11% to 9%), -18% for 5 mg CCX140-B (-26% to -8%), and -11% for 10 mg CCX140-B (-20% to -1%). We recorded a -16% difference between 5 mg CCX140-B and placebo (one-sided upper 95% confidence limit -5%; p=0·01) and a -10% difference between 10 mg CCX140-B and placebo (upper 95% confidence limit 2%; p=0·08). Adverse events occurred in 81 (73%) of 111 patients in the placebo group versus 71 (65%) of 110 patients in the CCX140-B 5 mg group and 68 (61%) of 111 patients in the CCX140-B 10 mg group; there were no renal events during the study.

INTERPRETATION:

Our data suggest that CCR2 inhibition with CCX140-B has renoprotective effects on top of current standard of care in patients with type 2 diabetes and nephropathy.

FUNDING:

ChemoCentryx.

项与 CCX-140 相关的新闻（医药）

2022-07-19

·药渡Daily

药渡第二期研讨会 | “勇于挑战，扬帆远航”之自身免疫疾病药物研发与中国企业出海机会

对于医药行业来说，自身免疫疾病已成为仅次于肿瘤的第二大赛道。全球市场规模早已超千亿美元。面对庞大的蓝海，国内外药企都在该领域展开了角逐。中国部分企业勇于挑战，在自免领域的国际竞争力和出海能力逐渐提高。直播时间2022年7月23日（周六）下午14:00-17:00将在药渡视频号隆重播出参与活动：找药渡小助手领取本次直播专属二维码，将专属二维码邀请给朋友、同事等预约观看，直播后以您邀请的实际观看人数进行统计，观看人数越多，获得的奖金越多，快快参与吧~进群了解会议请扫下方二维码（备注0723+公司+姓名）会议日程14:01-14:04大会致辞致辞人：朱迅教授14:05-14:50报告题目：自免领域的行业发展趋势与机会报告人：朱迅教授著名免疫学家14:50-15:35报告题目：红斑狼疮（SLE）、类风湿关节炎等自免疾病的研发机会及Case Study报告人：房健民博士荣昌生物首席执行官15:35-16:20报告题目：特应性皮炎及Th2相关疾病药物研发的机会和挑战报告人：郑伟博士康乃德首席执行官16:20-17:00圆桌讨论主持人：李靖博士讨论嘉宾：朱迅教授、房健民博士、潘武宾博士、郑伟博士、张翼中博士17:00-17:05会议总结致辞人：李靖博士嘉宾介绍朱迅 / 教授医学博士著名免疫学家吉林大学教授，博士生导师（往下可滑动）药渡战略总师、同写意新药英才俱乐部创始理事长、贝壳大学名誉校长、火石创造战略顾问；《药学进展》杂志副主编等。现兼任尚珹资本特聘医药专家；四环制药、深圳微芯生物独立董事；长春金赛药业、深圳奥萨医药高级顾问等。先后担任过国家新药咨询委员会成员、国家自然科学基金委生命科学部专家评审组成员，国家发改委生物技术专家咨询组成员，国家科技部中小企业技术创新基金评审委员，中华医学科学奖评审委员会委员，中国实验诊断杂志创始主编，药学进展杂志副主编，中国肿瘤生物治疗杂志编委，中国免疫学杂志编委等。李靖 / 博士药渡经纬，董事长毕业于美国威斯康星-密尔沃基大学，有机化学博士。中国海归留学生中成功的创业者之一。从2006年到现在，参与创办的企业包括：珅奥基医药科技有限公司，欧博方医药科技有限公司，药渡经纬信息科技有限公司, 本草资本。房健民 / 博士荣昌生物执行董事首席执行官兼首席科学官（往下可滑动）房健民博士，于2008年10月16日获委任为董事、首席执行官兼首席科学官，并于2020年5月22日调任为执行董事。房博士为本公司的共同创办人，主要负责本公司的整体管理、业务及策略。自成立以来，房博士一直是公司创新的主要驱动力，监管新药研发工作（涵盖从发现、靶点确认、CMC开发至临床研究）。他拥有超过20年的生物制药研发经验。房博士也担任全资附属公司荣昌生物医药研究（上海）有限公司、RemeGen Biosciences, Inc.及荣昌生物香港有限公司的董事。房博士于1998年5月获得加拿大Dalhousie University的生物学博士学位，于1997年至2000年在哈佛大学医学院外科/波士顿儿童医院担任博士后研究员，专注癌症研究。房博士于2010年3月获山东省人民政府认可为泰山学者。他自2012年12月起担任“重大新药创制”国家科技重大专项总体专家组成员，负责监管国家新药创制战略。房博士现为中国上海同济大学生命科学及科技学院的分子医学教授。他是中国药学会理事，中国医药生物技术协会“单克隆抗体专业委员会”副主任委员及中国医药创新促进会药物研发专业委员会副主任委员。他拥有超过40项专利。郑伟 / 博士康乃德联合创始人首席执行官（往下可滑动）郑伟博士自2012年联合创建康乃德以来，一直担任公司首席执行官和董事。他在自身免疫性疾病和炎症治疗领域拥有超过25年的从业经验。在创立康乃德之前，郑博士在Arena公司担任免疫学总监，领导该公司在炎症与自身免疫疾病领域的新药开发。在此之前，郑伟博士在ChemoCentryx公司担任首席科学家与生物部副总监，他发明并创建的以免疫细胞趋化因子受体(G蛋白偶联受体，GPCR) 的独一的新药筛选技术(细胞迁移的方向激活，或RAM)成为该公司的中心技术平台。由郑博士发现和主持开发的两个试验新药已在十九个国家进行了大规模临床试验。其中一项目CCX140已经完成临床II期的糖尿病试验并证明有效。郑博士曾是Ligand Pharmaceuticals公司的科学家，在斯坦福大学医学院从事人类抗体的基因重组研究。郑博士拥有16项新技术和新药相关的国际发明专利。郑博士在加州大学戴维斯分校获得生物化学和分子生物学博士学位。潘武宾 / 博士康乃德联合创始人总裁兼董事长（往下可滑动）潘武宾博士自 2012 年 5 月起担任康乃德总裁兼董事长。他在生物制药研发领域拥有超过25年的从业经验。在联合创立康乃德之前，潘博士作为联合创始人创建了Crown Bioscience, Inc.(中美冠科)公司，先后出任中国区总裁、总公司首席运营官和执行副总裁，CrownBio公司已成为在全球抗肿瘤药物研发外包领域主要的CRO之一。在创立CrownBio公司之前，潘博士在(深圳)清华源兴生物医药有限公司担任副总裁，分别组织和参与基因治疗、基因疫苗、肿瘤疫苗等药物及纳米、人体组织工程医疗产品研发等工作，为多种基因治疗生物制剂的开发做出了关键贡献。与此同时，潘博士还领导和参与了诸多生物医学产品的开发和推广。潘博士是加州大学伯克利分校博士后，在英国萨塞克斯大学获得生物学博士学位，在清华大学获得工商管理学硕士学位。张翼中 / 博士中天上海总经理（往下可滑动）2004年任职于台湾中央研究院，主要从事核酸药物及相关新一代检测技术开发，期间参与台湾自主核酸微数组芯片技术研发，亦成功开发利用适体－奈米金的快速高敏感单细菌检测技术及多项核酸适体筛选技术，并获得多项具开发潜力之免疫核酸适体。2015年进入中天集团后，积极布建下一代小核酸药物开发平台及相关多项专利技术，并致力于核酸药物的临床化。参与并主导多项核酸药物开发，累计发表20多项核酸药物及技术相关之发明专利。现任中天上海总经理，全面负责中天生计集团在大陆的业务。商务合作药渡经纬公司联系方式：赵先生 18613367352（微信同号）王女士 18001383271（微信同号）

基因疗法疫苗

2021-04-29

·GlobeNewswire

ChemoCentryx Reports First Quarter 2021 Financial Results

-- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the United States, Europe and Japan; PDUFA goal date of July 7, 2021, with Advisory Committee scheduled for May 6 -- -- Novel orally administered checkpoint inhibitor CCX559 featured at American Association for Cancer Research Annual Meeting, expected to enter clinical development as a next generation cancer treatment in Q2 2021 -- -- Other avacopan programs: severe Hidradenitis Suppurativa (HS) Phase III and Lupus Nephritis development initiation on track for 2H 2021 -- -- $424 million in cash and investments at March 31, 2021 -- -- Conference call today at 5:00 p.m. Eastern Time -- SAN CARLOS, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced financial results for the first quarter ended March 31, 2021 and provided an overview of recent corporate highlights. "Momentum builds with each passing quarter, bringing us closer to our goal of bringing novel, precisely targeted medicine to those that need it most,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “At our R&D Day earlier this month, two world-renowned clinicians outlined the unmet needs in ANCA-associated vasculitis and the data driving their conviction that avacopan could become a landscape-changing therapy. We are well prepared and look forward to providing our views at the FDA Advisory Committee meeting on this topic in just a few days. During our R&D Day we also took the opportunity to establish how our novel small molecule PD-1/PD-L1 inhibitor CCX559 could transcend current limitations in the treatment of cancer. Meanwhile we are progressing toward our next cycle of clinical trials: a Phase III trial of avacopan in patients with severe HS; the initiation of clinical development of avacopan in lupus nephritis, and our first in human studies of the novel orally administered checkpoint inhibitor CCX559 in cancer patients. We look forward to an historic year of 2021 at ChemoCentryx, and we will devote all our energies to making the dream of breakthrough new therapies a reality for patients.” Key First Quarter 2021 Highlights and Recent Developments First Quarter 2021 Financial Results Revenue was $10.4 million for the first quarter of 2021, compared to $6.0 million for the same period in 2020. The increase in revenue from 2020 to 2021 was principally attributable to the $10.0 million milestone from Vifor for the February 2021 acceptance of the Japanese NDA for avacopan in the treatment of ANCA vasculitis. Research and development expenses were $23.4 million for the first quarter of 2021, compared to $19.3 million for the same period in 2020. The increase from 2020 to 2021 was primarily attributable to the manufacture of commercial drug supply in anticipation of the launch of avacopan for the treatment of ANCA vasculitis and costs associated with the advancement of CCX559, the Company’s orally-available small molecule checkpoint (PD-1/PD-L1) inhibitor. These increases were partially offset by lower Phase II related expenses due to the completion of patient enrollment of the avacopan AURORA Phase IIb clinical trial in patients with HS and the discontinuation of further clinical development of CCX140 in FSGS in 2020. General and administrative expenses were $16.3 million for the first quarter of 2021, compared to $8.8 million for the same period in 2020. The increase from 2020 to 2021 was primarily due to higher employee-related expenses, including those associated with the Company’s commercialization planning efforts, and higher professional fees. Net loss for the first quarter of 2021 was $29.7 million, compared to net loss of $21.7 million for the same period in 2020. Total shares outstanding at March 31, 2021 were approximately 69.7 million shares. Cash, cash equivalents and investments totaled $424.2 million at March 31, 2021. The Company expects to utilize cash, cash equivalents and investments in the range of $145 million to $155 million in 2021. Conference Call and Webcast The Company will host a conference call and webcast today, April 29, 2021 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 3963565. A live and archived audio webcast can be accessed through the Investors section of the Company's website at . The archived webcast will remain available on the Company's website for fourteen (14) days following the call. About ChemoCentryx ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. Forward-Looking StatementsChemoCentryx cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding the achievement of anticipated goals and milestones, whether avacopan will be approved by the FDA, EMA or PMDA for the treatment of ANCA-associated vasculitis, the timing of the FDA’s, EMA’s and PMDA’s decision on the NDA, MAA, and JNDA, respectively, the timing of the potential commercial launch of avacopan in ANCA-associated vasculitis, whether avacopan will be an effective treatment in other indications such as severe HS, C3G and lupus nephritis, whether a Phase III trial of avacopan in patients with severe HS will commence in Q4 2021, whether avacopan for lupus nephritis and CCX559 will enter clinical trials in 2021 in Q4 2021 and Q2 2021, respectively, whether actual cash utilization will fall within projections and whether the Company's drug candidates will be shown to be effective in ongoing or future clinical trials. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the SEC, including ChemoCentryx's Annual Report on Form 10-K filed with the SEC on March 1, 2021 and its other reports which are available from the SEC's website () and on ChemoCentryx's website () under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Contacts:Susan M. KanayaExecutive Vice President,Chief Financial and Administrative Officerinvestor@chemocentryx.com Media:Stephanie Tomei408.234.1279media@chemocentryx.com Investors:Burns McClellanLee Roth212.213.0006 lroth@burnsmc.com

小分子药物财报AACR会议

2018-03-20

·BioPortfolio

ChemoCentryx Inc CCXI Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27022018] Prices from USD $250

Summary ChemoCentryx Inc ChemoCentryx is a biopharmaceutical company that discovers, develops and commercializes orallyadministered therapeutics for the treatment of cancer, autoimmune diseases, and inflammatory disorders. The company's pipeline products include C5aR programs, CCR2 program, CCR9 program, and CCR1 program. ChemoCentryx's C5aR Program is for the treatment of antineutrophil cytoplasmic antibody associated renal vasculitis. The company's CCR2 Program provides CCX140 for the treatment of diabetic nephropathy, a form of kidney disease and CCX872 for the treatment of pancreatic cancer. Its CCR9 Program is for the treatment of patients with Crohn's disease and CCX507 is for the treatment of inflammatory bowel disease. ChemoCentryx is headquartered in Mountain View, California, the US. ChemoCentryx Inc CCXI Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

抗体并购

100 项与 CCX-140 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16066

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾病综合征	临床2期	美国	ChemoCentryx, Inc.	2018-10-01
局灶性节段性肾小球硬化症	临床2期	美国	ChemoCentryx, Inc.	2018-05-17
局灶性节段性肾小球硬化症	临床2期	澳大利亚	ChemoCentryx, Inc.	2018-05-17
局灶性节段性肾小球硬化症	临床2期	加拿大	ChemoCentryx, Inc.	2018-05-17
局灶性节段性肾小球硬化症	临床2期	法国	ChemoCentryx, Inc.	2018-05-17
局灶性节段性肾小球硬化症	临床2期	意大利	ChemoCentryx, Inc.	2018-05-17
局灶性节段性肾小球硬化症	临床2期	新西兰	ChemoCentryx, Inc.	2018-05-17
局灶性节段性肾小球硬化症	临床2期	波兰	ChemoCentryx, Inc.	2018-05-17
局灶性节段性肾小球硬化症	临床2期	英国	ChemoCentryx, Inc.	2018-05-17
白蛋白尿	临床2期	荷兰	ChemoCentryx, Inc.	2011-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03703908 (CTgov)	临床2期	局灶性节段性肾小球硬化症 \| 肾病综合征	5	CCX140-B	膚餘選艱廠廠鑰製築積(觸襯選鬱鬱膚襯觸淵齋) = 願廠鑰願網遞憲鏇齋鑰築獵遞顧憲顧鹹鏇鹽遞 (範醖鬱簾選築夢觸齋廠, 簾築選顧鹹網襯顧構鬱 ~ 餘蓋鹽廠膚網憲廠繭築) 更多	-	2024-02-06
LUMINA-1 (ERA2021)	临床2期	局灶性节段性肾小球硬化症	-	CCX140 5 mg once daily	艱廠顧廠構鹽膚衊觸憲(襯觸築壓簾願淵醖選襯) = 艱遞繭構鏇積壓蓋餘醖顧觸鏇壓襯鏇網範蓋餘 (積簾襯糧夢膚鑰襯廠鏇 )	不佳	2021-05-29
				CCX140 15 mg twice-daily	艱廠顧廠構鹽膚衊觸憲(襯觸築壓簾願淵醖選襯) = 網範顧餘糧築選窪鹽蓋顧觸鏇壓襯鏇網範蓋餘 (積簾襯糧夢膚鑰襯廠鏇 )
NCT03536754 (LUMINA-1, BusinessWire) 人工标引	临床2期	局灶性节段性肾小球硬化症	46	CCX-140	廠糧襯願齋觸網簾廠餘(醖遞鹽膚蓋餘範夢夢淵) = none during the blinded trial 衊壓鬱製醖顧築製餘製 (顧獵餘夢願遞齋網鹽顧 ) 更多	不佳	2020-05-18
				Placebo